4893 items matching your search terms.

NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol

Askie, L Brocklehurst, P Darlow, B Finer, N Schmidt, B Tarnow-Mordi, W NeOProM Collaborative Group,
BMC PEDIATRICS, 2011     DOI:doi:10.1186/1471-2431-11-6

Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care

Asmis, TR Powell, E Karapetis, CS Jonker, DJ Tu, D Jeffery, M Pavlakis, N Gibbs, P Zhu, L Dueck, D-A Whittom, R Langer, C O'Callaghan, CJ
ANNALS OF ONCOLOGY, 2011     DOI:10.1093/annonc/mdq309

A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma after induction chemotherapy

Baas, P Buikhuisen, W Dalesio, O Vincent, A Pavlakis, N Van Klaveren, R Schramel, F Custers, F Schouwink, H Burgers, SA

How long have I got? Estimating typical, best and worst case scenarios for patients starting first-line chemotherapy for extensive small cell lung cancer: a systematic review of contemporary randomised trials

Bagia, M Houghton, B Boyer, M Millward, M Stockler, M

Maintenance chemotherapy in extensive small cell lung cancer: a meta-analysis of randomised trials

Bagia, M Houghton, B Brown, C Boyer, M Millward, M Stockler, M

Novel targeted therapies and vaccination strategies for mesothelioma

Bagia, M Nowak, AK
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2011     DOI:10.1007/s11864-011-0149-1

Authors' reply

Baigent, C. Emberson, J. Blackwell, L. Keech, A. Collins, R.
THE LANCET, 2011     DOI:10.1016/S0140-6736(11)60263-8

Efficacy and safety of more intensive lowering of LDL cholesterol: authors' reply [letter]

Baigent, C Emberson, J Blackwell, L Keech, A Collins, R for the Cholesterol Treatment Trialists' Collaboration,
LANCET, 2011     DOI:Doi: 10.1016/s0140-6736(11)60263-8

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C. Landray, M. J. Reith, C. Emberson, J. Wheeler, D. C. Tomson, C. Wanner, C. Krane, V. Cass, A. Craig, J. Neal, B. Jiang, L. Hooi, L. S. Levin, A. Agodoa, L. Gaziano, M. Kasiske, B. Walker, R. Massy, Z. A. Feldt-Rasmussen, B. Krairittichai, U. Ophascharoensuk, V. Fellstrom, B. Holdaas, H. Tesar, V. Wiecek, A. Grobbee, D. de Zeeuw, D. Gronhagen-Riska, C. Dasgupta, T. Lewis, D. Herrington, W. Mafham, M. Majoni, W. Wallendszus, K. Grimm, R. Pedersen, T. Tobert, J. Armitage, J. Baxter, A. Bray, C. Chen, Y. Chen, Z. Hill, M. Knott, C. Parish, S. Simpson, D. Sleight, P. Young, A. Collins, R.
LANCET, 2011     DOI:10.1016/s0140-6736(11)60739-3

Comparison of radiotherapy treatment plans for left-sided breast cancer patients based on three- and four-dimensional computed tomography imaging

Bedi, C. Kron, T. Willis, D. Hubbard, P. Milner, A. Chua, B.
CLINICAL ONCOLOGY (ROYAL COLLEGE OF RADIOLOGISTS), 2011     DOI:10.1016/j.clon.2011.04.004

Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data

Bell, KJL Kirby, A Hayen, A Irwig, L Glasziou, P
BMJ (CLINICAL RESEARCH ED.), 2011     DOI:10.1136/bmj.d12

Incorporating novel biomarkers significantly improves risk stratification for coronary heart disease patients: the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial.

Blankenberg, S Tonkin, A Kirby, A Colquhoun, D Hunt, D Keech, A Nestel, P Glasziou, P Sullivan, D Thompson, P West, M White, H Zeller, T Hague, W Mann, K Simes, J on behalf of the LIPID Study Investigators,

Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?

Blinman, P McLachlan, SA Nowak, AK Duric, VM Brown, C Wright, G Millward, M Fong, K Stockler, MR
LUNG CANCER, 2011     DOI:10.1016/j.lungcan.2010.08.007

Lung cancer clinician' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile

Blinman, P McLachlan, S Nowak, A Duric, V Wright, G Millward, M Brown, C Coskinas, X Fong, K Stockler, M on behalf of the Australasian Lung Cancer Trials Group,

Gold seed fiducial markers for prostate radiation therapy: describing prostate motion

Brown, A Gebski, V Beldham-Collins, R Hardcastle-Fowler, T Do, V Turner, S